Doylestown, PA June 23, 2008 - Serigene LLC, a developer of a PCR-based diagnostic testing platform, has appointed Professor Robert A. Bohrer to the Company’s Board of Directors.
“We are pleased to welcome Professor Robert A. Bohrer to our Board of Directors,” commented Sergey Ilyin, PhD, Chief Scientific Officer of Serigene. “Dr. Bohrer draws upon nearly 40 years of legal experience and his insight will be invaluable to the Board and the Company as a whole”
About Robert A. Bohrer, J.D. Professor Bohrer practiced with the Chicago law firm of Bell, Boyd & Lloyd before returning to academia. Since 1984 he has focused primarily on the legal issues raised by developments in biotechnology and pharmaceutical policy, as one of the first law professors in the U.S. to focus on a wide range of legal issues affecting the development of biotechnology. Bohrer is executive editor of Biotechnology Law Report. He previously served as director of Biotechnology Programs at the University of California at San Diego’s Center for Molecular Genetics and and on the board of directors of the La Jolla Institute for Molecular Medicine. Bohrer was the only law professor to serve on the board of directors of the Biotechnology Institute of the U.S. Patent and Trademark Office. Professor Bohrer’s book, A Guide to Biotechnology Law and Business was released in the fall of 2007.
About Serigene LLC Serigene was founded to introduce a rigorous and cutting edge standard in field-testing to the diagnostic community. Serigene has developed a proprietary point of care integrated testing technology consisting of a Real Time PCR reader (RT-reader) with a proprietary Serigene cartridge. The Serigene cartridge has significant advantage over alternatives in terms of flexibility, number of tests, and detection speed. More information about Serigene can be found at the company website at www.serigene.com.
